Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies

Neurology

Volumn 74, Issue 20, 2010, Pages 1598-1606

  Onofrj, Marco ^a   Bonanni, Laura ^a   Manzoli, Lamberto ^a   Thomas, Astrid ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ASSAULT; CAREGIVER; CATATONIA; CLINICAL FEATURE; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DELUSION; DEMENTIA; DEMOGRAPHY; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HOSPITAL ADMISSION; HUMAN; INTERVIEW; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SENSORY DYSFUNCTION; SHY DRAGER SYNDROME; SOMATOFORM DISORDER;

EID: 77952488915     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181df09dd     Document Type: Article

References (40)

1. Wolters ECH, van der Werf YD, van den Heuvel OA. Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J Neurol 2008;255 suppl 5:48-56.
2. Olanow CW, Stern B, Sethi K. The scientific and clinical basis for the treatment of Parkinson's disease. Neurology 2009;72 suppl 4:1-136.
3. Li X, Sundquist J, Hwang H, Sundquist K. Impact of psychiatric disorders on Parkinson's disease: a nationwide follow-up study from Sweden. J Neurol 2008;255:31-36.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-Text Revised. Washington, DC: American Psychiatric Association; 2000.
5. Crimlisk HL, Bhatia K, Cope H, David A, Marsden CD, Ron MA. Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ 1998;316:582-586.
6. Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology 2003;61:1479-1485.
7. Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol 1995;52:802-810.
8. Factor SA, Podshalny GD, Molho ES. Psychogenic movement disorders: frequency, clinical profile and characteristics. J Neurol Neurosurg Psychiatry 1995;59:406-412.
9. Saint-Cyr JA, Taylor AE, Nicholson K. Behavior and the basal ganglia. Adv Neurol 1995;65:1-28.
10. Costa A, Peppe A, Carlesimo GA, Salamone G, Caltagi-rone C. Neuropsychological correlates of alexithymia in Parkinson's disease. J Int Neuropsychol Soc 2007;13:980-992.
11. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008;23:690-699.
12. Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 2004;7:587-588.
13. Babinski J. Définition de l'hystérie. Rev Neurol 1901;9: 1074-1080.
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-349. (Pubitemid 351289042)
15. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17. Fahn S, Elton RL, Members of the Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marden CD, Calne DB, Goldstein M, eds. Recent Development in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-164.
18. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium [erratum 2005;65:1992]. Neurology 2005;65:1863-1872.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
20. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
21. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98. (Pubitemid 29155424)
22. McKhann GM, Albert MS, Grossman M, Miller B, Dick-son D, Trojanowski JQ, Work Group on Frontotemporal Dementia and Pick's Disease. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803-1809.
23. Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord 2001;16:197-201.
24. Folstein NF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for clinician. J Psychiatry Res 1975;12:189-198.
25. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55:1621-1626.
26. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-256.
27. Beck AT, Steer RA, Brown GK. BDI-II Manual. London: The Psychological Corporation; 1996.
28. Derogatis LR. SCL-90-R: Symptom Checklist-90-R. Administration, Scoring and Procedures Manual. Minneapolis: National Computer Systems; 1994.
29. Jurica PJ, Leitten CL, Mattis S. DRS-2 Dementia Rating Scale 2. Psychological Assessment Resources; 2001.
30. Declaration of Helsinki. Recommendation guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
31. Cotard, J. Du delire des negations. Arch Neurol 1882;4: 152-170.
32. Deutsche Gesellschaft für Neurologie. Leitlinien-Parkin-son- Syndrome; 4.3.1.1. Therapieeinleitung. Available at: www.dgn.org/168.0htlm#926. Accessed December 1, 2009.
33. Kamigaichi R, Kubo S, Ishikawa K, et al. Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report. Eur J Neurol 2009;16:e6.
34. Suzuki K, Awata S, Nakagawa K, Takano T, Matsuoka H. Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy. Mov Disord 2006;21:123-124. (Pubitemid 43273768)
35. Siri C, Cilia R, De Gaspari D, et al. Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. Neurol Sci Epub 2009.
36. Marshall JC, Halligan PW, Fink GR, Wade DT, Frackow-iak RS. The functional anatomy of a hysterical paralysis. Cognition 1997;64:B1-8.
37. Vuilleumier P, Chicherio C, Assal F, Schwartz S, Slos-man D, Landis T. Functional neuroanatomical correlates of hysterical sensorimotor loss. Brain 2001;124: 1077-1090.
38. Northoff G, Kötter R, Baumgart F, et al. Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation. Schizophr Bull 2004;30:405-427.
39. Merskey H. Conversion, dissociation, or doxomorphic disorder. In: Halligan W, Bass C, Marshall J. Contemporary Approaches to the Study of Hysteria: Clinical and Theoretical Perspectives. Oxford, UK: Oxford University Press; 2001:171-183.
40. Shorter E. Hysteria and catatonia as motor disorders in historical context. Hist Psychiatry 2006;17:461-468.